UPM-Kymmene Oyj
SWB:RPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
UPM-Kymmene Oyj
SWB:RPL
|
FI |
|
M
|
Manulife Financial Corp
F:MLU
|
CA |
|
Alphabet Inc
LSE:0HD6
|
US |
|
K
|
Koninklijke Philips NV
DUS:PHIA
|
NL |
|
Brunello Cucinelli SpA
MIL:BC
|
IT |
|
Soleno Therapeutics Inc
F:6XC
|
US |
|
Allianz SE
XETRA:ALV
|
DE |
|
I
|
Innocan Pharma Corp
DUS:IP4
|
IL |
|
A
|
Alibaba Group Holding Ltd
HKEX:9988
|
CN |
Wall St Price Targets
RPL Price Targets Summary
UPM-Kymmene Oyj
According to Wall Street analysts, the average 1-year price target for RPL is 27.39 EUR with a low forecast of 21.16 EUR and a high forecast of 33.52 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPL's stock price target?
Price Target
27.39
EUR
According to Wall Street analysts, the average 1-year price target for RPL is 27.39 EUR with a low forecast of 21.16 EUR and a high forecast of 33.52 EUR.
What is the Revenue forecast for UPM-Kymmene Oyj?
Projected CAGR
1%
Over the last 14 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 8 years is 1%.
What is the Operating Income forecast for UPM-Kymmene Oyj?
Projected CAGR
13%
Over the last 14 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 8 years is 13%.
What is the Net Income forecast for UPM-Kymmene Oyj?
Projected CAGR
25%
Over the last 14 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 4 years is 25%.
